TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]
TScan Therapeutics, Inc. (TCRX)
Company Research
Source: Yahoo! Finance
CIBMTR; 8/8 (100%) patients in treatment arms are relapse-free and show complete donor chimerism Announced the clearance of two additional INDs for Solid Tumor Program: TSC-201-B0702 targeting MAGE-C2 on HLA-B*07:02 and TSC-204-A0101 targeting MAGE-A1 on HLA-A*01:01 Solid tumor clinical trial actively enrolling, with initial data for singleplex and multiplex cohorts anticipated in 2024 Expands leadership team with key appointments and promotions Cash, cash equivalents, and marketable securities continues to fund operations into 2026 WALTHAM, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today reported financial results for the three months and full year ended December 31, 2023, and provided a business update. “The advancements we made across our pipeline in 2023 hav
Show less
Read more
Impact Snapshot
Event Time:
TCRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TCRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TCRX alerts
High impacting TScan Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TCRX
News
- TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting [Yahoo! Finance]Yahoo! Finance
- TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual MeetingGlobeNewswire
- TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewswire
- TScan Therapeutics, Inc. (NASDAQ: TCRX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $10.00 price target on the stock.MarketBeat
- TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting [Yahoo! Finance]Yahoo! Finance
TCRX
Earnings
- 11/9/23 - Beat
TCRX
Sec Filings
- 4/23/24 - Form SC
- 4/23/24 - Form 4
- 4/23/24 - Form 4
- TCRX's page on the SEC website